Comparative Pharmacology
Head-to-head clinical analysis: CARVEDILOL versus PROCAINE HYDROCHLORIDE W EPINEPHRINE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CARVEDILOL versus PROCAINE HYDROCHLORIDE W EPINEPHRINE.
CARVEDILOL vs PROCAINE HYDROCHLORIDE W/ EPINEPHRINE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Carvedilol is a nonselective beta-adrenergic receptor antagonist (beta-1, beta-2) and alpha-1 adrenergic receptor antagonist. It causes vasodilation and reduces heart rate, myocardial contractility, and blood pressure. It also has antioxidant and anti-proliferative effects.
Procaine is a local anesthetic that blocks voltage-gated sodium channels, preventing nerve impulse conduction. Epinephrine causes vasoconstriction via alpha-1 adrenergic receptor agonism, reducing absorption of procaine and prolonging its effect.
Heart failure: Initial 3.125 mg orally twice daily, titrate every 2 weeks to 6.25 mg, 12.5 mg, then 25 mg twice daily as tolerated. Target dose: 25 mg twice daily (≤85 kg) or 50 mg twice daily (>85 kg). Hypertension: Initial 6.25 mg orally twice daily, titrate every 1-2 weeks to 12.5 mg, then 25 mg twice daily. Maximum: 50 mg twice daily.
2% procaine hydrochloride with epinephrine 1:200,000: Local infiltration or nerve block: up to 25 mL (500 mg procaine) as a single dose; maximum total dose 1000 mg per procedure. For epidural or spinal anesthesia: 5-20 mL (100-400 mg) as needed.
None Documented
Clinical Note
moderateCarvedilol + Digitoxin
"Carvedilol may increase the bradycardic activities of Digitoxin."
Clinical Note
moderateCarvedilol + Deslanoside
"Carvedilol may increase the bradycardic activities of Deslanoside."
Clinical Note
moderateCarvedilol + Acetyldigitoxin
"Carvedilol may increase the bradycardic activities of Acetyldigitoxin."
Clinical Note
moderateCarvedilol + Ouabain
"Carvedilol may increase the bradycardic activities of Ouabain."
None Documented
Terminal elimination half-life is 7-10 hours. Steady-state concentrations are achieved within 2-3 days. Clinical context: Twice-daily dosing provides consistent beta-blockade and vasodilation.
Procaine: 40–84 seconds (plasma), due to rapid hydrolysis. The terminal elimination half-life of procaine is approximately 7–8 minutes after hydrolysis, but the clinical effect is terminated by redistribution and metabolism. Epinephrine: 2–3 minutes.
Primarily hepatic metabolism, with less than 2% excreted unchanged in urine. Metabolites are excreted in bile and feces; renal clearance of metabolites accounts for ~16% of total clearance. Fecal excretion of metabolites is ~60%.
Renal excretion of procaine is minimal as it is rapidly hydrolyzed by plasma pseudocholinesterase to para-aminobenzoic acid (PABA) and diethylaminoethanol (DEAE). Less than 2% of unchanged procaine is excreted in urine. Metabolites are further processed and eliminated renally. Epinephrine is metabolized by catechol-O-methyltransferase and monoamine oxidase; metabolites are excreted in urine.
Category C
Category A/B
Alpha/Beta-Blocker
Alpha/Beta Agonist